If you want to be in the know about what’s going on at our organization, you’ve come to the right place!
Having an adequate supply of treatment products at home is critical to achieve safe patient care and continuity of treatment.
On March 27th, experts from NHF answered your questions regarding changes in insurance in our townhall webinar: Insurance: Coping During COVID-19.
Meditation is powerful. If you’re still unsure whether or not the practice is worth trying, check out these top benefits of meditation and consider how they can help improve your life.
MASAC's latest set of recommendations cover the use and management of emicizumab, the latest products licensed to treat bleeding disorders, integrating the CDC's opioid prescribing guidelines into bleeding disorders care, and bleeding prophylaxis for patients undergoing gastrointestinal endoscopies.
On March 20th, NHF’s President and CEO answered your questions about how COVID-19 affects our community.
When bad things happen, how do we act individually, and how can we come together as a society? How can we be kind in times of darkness?
Information and techniques you and your family can use to stay healthy during the COVID-19 pandemic.
Do you have questions regarding insurance coverage in light of the COVID-19 pandemic? We're here to help.
The halted trials were investigating concizumab prophylaxis treatment in hemophilia A and B patients regardless of inhibitor status.
NHF will update this page as more statements about product supply becomes available.
Whether it’s a few hours or a long commitment, volunteering not only supports those around you but positively influences you as well.
A statement from Dr. Valentino addressing the concerns of the community regarding the rapidly evolving COVID-19 situation.
Living a full and altruistic life is about more than just doing your best. It’s about sharing your best with others around you and connecting with them through our inherent need to tell stories.
Takeda responded to the HFA-NHF letter late yesterday regarding the recall of two lots of VONVENDI von Willebrand factor.
The National Hemophilia Foundation will continue to monitor the rapidly changing situation regarding COVID-19 and provide regular updates to our community.
XINITY® is currently indicated for the control and prevention of bleeding episodes and for perioperative management in adults and children, 12 years of age or older, with hemophilia B.
More than 400 people affected by bleeding disorders asked their legislators to take action on the Hemophilia SNF Access Act
We will provide updated guidance if new information has implication for the bleeding disorders community.
Did you know you can give back by supporting small businesses? Here are some hows, whys and benefits of supporting small businesses for your altruistic lifestyle.
On February 28th, Genentech released a statement relating to the supply of Hemlibra as it relates to 2019-nCoV (novel coronavirus).
On February 27th, HFA and NHF submitted a letter to Takeda focusing on preliminary questions regarding the recall.
HFA and NHF recognize that recalls can be unsettling for many in the bleeding disorders community. We are in communications with Takeda to obtain additional detailed and timely information.
If you want your child to start on the right path, help them get involved in their community and start volunteering today.
This is a six-part activity designed to increase healthcare providers' knowledge of the treatment of hemophilia.
If you’re still not sure what you’re doing over spring break, check out these ideas for how you can have fun and give back.
The Physical Therapy Excellence Fellowship is meant to provide support PTs interested in conducting research or clinical projects related to the care of patients with hemophilia.
This resource was created to provide much needed guidance to emergency department personnel who may encounter patients presenting with a bleeding disorder.
The impact of an FDA "Listening Session" on gene therapy for hemophilia.
ESPEROCT® is a long-acting recombinant product for the treatment of hemophilia A.
You can give the most lovely Valentine’s Day gift by giving back to your community. Check out 14 altruistic ways to celebrate this special day.
NHF maintains its prestigious 4-star rating from Charity Navigator, the largest independent charity evaluator in the US.
The organizations continue to monitor the outbreak.
Don’t let winter get you down. Resist seasonal affective disorder with five tips to stay positive during the coldest season.
The new guidance issued by the U.S. Food and Drug Administration seeks to support both innovation and patient safety by providing an important regulatory framework for developers of investigational gene therapies.
The Green Park Collaborative and the National Hemophilia Foundation launch project to develop a PROM to measure mental health outlook.
Our words are powerful and should be handled with respect. Because they can impact others, choose yours wisely with these helpful tips.
This study was based on a systematic literature review of peer-reviewed articles relevant to VWD and pregnancy, published between January 1982 and May 2019.
How can we be kind in times of darkness? Today we’re going to talk about just that, and how we can continue to live altruistically when facing heart-wrenching times.
Nationally recognized researcher Dr. Leonard Valentino to lead the Foundation into the future.
Groups argue patients need a quick resolution to ensure access to care.
The group of patients who participated in this study were teenagers living with hemophilia A and B, who averaged 16 years of age.
Self-defeating thoughts can come when we least expect them and tear down our self-esteem and break our spirits. Stand up to them and choose joy instead with five ways to overcome self-defeating thoughts.
The activity is intended for emergency medicine physicians, hematologists, pediatricians, nurses, and other healthcare professionals who manage patients with hemophilia.
On December 23rd, the BioMarin submitted a Biologics License Application for valoctocogene roxaparvovec to the U.S. Food and Drug Administration.
Sangamo transferred the investigational new drug application for their hemophilia A gene therapy candidate to Pfizer, which will now lead its phase 3 clinical development.